Literature DB >> 8993512

Schedule-dependent efficacy of camptothecins in models of human cancer.

P J Houghton1, C F Stewart, W C Zamboni, J Thompson, X Luo, M K Danks, J A Houghton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8993512     DOI： 10.1111/j.1749-6632.1996.tb26388.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

1.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer
Journal:  J Clin Oncol       Date:  2018-08-09       Impact factor: 44.544

2.  Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

Authors:  Sophie Pinel; Pascal Chastagner; Jean-Louis Merlin; Christian Marchal; Alphonse Taghian; Muriel Barberi-Heyob
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Initial testing of topotecan by the pediatric preclinical testing program.

Authors:  Hernan Carol; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Amy Watkins; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

Review 4.  Topotecan. A review of its potential in advanced ovarian cancer.

Authors:  R N Brogden; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

5.  Prospective use of the single-mouse experimental design for the evaluation of PLX038A.

Authors:  Samson Ghilu; Qilin Li; Shaun D Fontaine; Daniel V Santi; Raushan T Kurmasheva; Siyuan Zheng; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-11       Impact factor: 3.333

6.  In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer Model.

Authors:  Katayoun Derakhshandeh; Gunther Hochhaus; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

Review 7.  How translational modeling in oncology needs to get the mechanism just right.

Authors:  James W T Yates; David A Fairman
Journal:  Clin Transl Sci       Date:  2021-11-12       Impact factor: 4.689
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.